demonstrated that after silencing the ABCB1 gene by CRISPR/Cas9 in osteosarcoma MDR cell lines, the drug resistance against ABCB1 substrate doxorubicin was reversed while the response to non‐ABCB1 substrate cisplatin was unchanged.24 The gene discussed is ABCB1; the disease is osteosarcoma.